Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PepFactor Scalp is a hair restoration treatment developed by ReGen Factor, an Australian biotechnology company. The active ingredient is a recombinant basic fibroblast growth factor (bFGF), a large molecule protein designed to treat androgenetic alopecia (AGA) in both men and women. The mechanism of action involves bFGF binding to fibroblast growth factor receptors, which stimulates the proliferation of dermal papilla cells, enlarges hair follicles, and induces the anagen (growth) phase of the hair cycle. Additionally, it promotes the production of collagen and elastin in the scalp to improve the hair growth environment. It is typically administered via microneedling followed by topical application of the serum. While currently marketed as a cosmeceutical, the company has initiated clinical development paths for pharmaceutical applications, including FDA pre-IND planning.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PepFactor Scalp.